Findings support clesrovimab as option to protect children entering second RSV season
Merck reported phase 3 SMART trial results for clesrovimab (Enflonsia) in 276 children entering their second RSV season. The FDA accepted Merck’s application to expand approval to children up to age 2. Second-season medically attended LRTI incidence was 7.3% and RSV hospitalizations 3.0%. Safety was similar to first season.
How this was made
The 30-second read
Why it matters
The SMART Phase 3 second-season results show no meaningful difference in RSV-associated outcomes versus palivizumab from the first season, while the FDA accepted Merck’s application to expand clesrovimab use to children up to age 2 entering their second RSV season.
Market read
Traders get a concrete regulatory milestone (FDA acceptance) paired with second-season clinical data, which can re-rate the probability-weighted value of clesrovimab’s expanded indication.
What to watch
The article reports safety and incidence rates but does not quantify comparative efficacy versus nirsevimab in the second season, nor does it provide commercial pricing or reimbursement details that drive near-term sales.
Background
Clesrovimab (Enflonsia) is a long-acting RSV monoclonal antibody; palivizumab was discontinued in 2025 after nirsevimab (Beyfortus) became widely available.
Ticker impact
Merck’s clesrovimab FDA application was accepted to expand approval for children up to age 2 entering their second RSV season.
Moderate positive bias for MRK as FDA review advances toward a March 22, 2027 target action date.
The article discloses FDA acceptance (a concrete regulatory milestone) and trial outcomes for a second-season dose, both of which can affect future revenue expectations and uptake, though no approval decision is yet granted.
Market effects
Strengthens the competitive case for long-acting RSV monoclonals beyond first-season use, potentially shifting payer and guideline expectations toward broader seasonal coverage.
Trial spans 27 countries and territories, which may support global commercialization narratives for RSV prevention.
RSV remains a major pediatric hospitalization driver worldwide, so expanded indications can influence global procurement and seasonal immunization strategies.
Counterpoint
FDA acceptance is not approval; uptake and revenue impact may be limited until the agency grants expanded labeling and real-world effectiveness is confirmed.
Key entities
- companyMerck
Sponsor of clesrovimab; FDA accepted its application to expand approval for children up to age 2 entering their second RSV season.
- drugClesrovimab (Enflonsia)
Long-acting RSV monoclonal antibody; Phase 3 SMART second-season data and FDA expansion application acceptance.
- regulatorFDA
Accepted Merck’s application; set a target action date of March 22, 2027.
- clinical_trialSMART trial
Phase 3 study evaluating clesrovimab dosing across first and second RSV seasons.
